Pfizer continued losses for seven consecutive sessions

Pfizer (NYSE:PFE [https://seekingalpha.com/symbol/PFE]) continued losses for seven consecutive sessions, as the stock closed 0.79% lower at $24.54 on Tuesday.

In the preceding six sessions, the company lost over 6.4%. Shares of the company have gone down by over 7% compared to a gain of 13.14% in the broader S&P 500 Index in 2025.

Looking at Seeking Alpha’s Quant rating [https://seekingalpha.com/symbol/PFE/ratings/quant-ratings], PFE has a HOLD rating with a score of 3.45 out of 5. The company was rated A+ for profitability, while it got a D- for growth and a C- for momentum.

According to Wall Street analysts [https://seekingalpha.com/symbol/PFE/ratings/sell-side-ratings], eight rated the stock a Buy or above, while 15 rated it a Hold, while one considered it a Sell and lower.

However, Oakoff Investments [https://seekingalpha.com/article/4829048-pfizer-stock-q3-catalyst-for-bullish-resurgence-earnings-preview], a quantitative research analyst, rated PFE a Buy, by reporting that Pfizer's stock is poised for recovery, driven by recent corporate news and a three-year reprieve on drug-import tariffs from the Trump administration, strengthening the bullish case despite prior market reactions.

Another analyst, Walter Zelezniak Jr [https://seekingalpha.com/article/4828199-pfizer-offers-high-yield-capital-appreciation-opportunities-technical-analysis] rated a Buy, reporting that technical analysis shows PFE above its 30-week EMA, with bullish short- and long-term momentum and strong buying volume from institutional investors.

MORE ON PFIZER

* Pfizer's Q3: The Catalyst For A Bullish Resurgence (Earnings Preview) [https://seekingalpha.com/article/4829048-pfizer-stock-q3-catalyst-for-bullish-resurgence-earnings-preview]
* Pfizer: Mastering The Art Of The Deal With Metsera - Upgraded To Buy [https://seekingalpha.com/article/4828589-pfizer-mastering-the-art-of-the-deal-with-metsera-upgraded-to-buy]
* Why The Pfizer-Trump Pharma Deal Is A Win For Branded Pharma, But Not For Consumers [https://seekingalpha.com/article/4828341-why-pfizer-trump-pharma-deal-is-win-for-branded-pharma-not-for-consumers]
* Seeking Alpha's healthcare quant picks ahead of Q3 earnings: McKesson, Incyte top-rated stocks [https://seekingalpha.com/news/4503551-seeking-alphas-healthcare-quant-picks-ahead-of-q3-earnings-mckesson-incyte-top-rated-stocks]
* Pfizer succeeds in late-stage trial for Tukysa breast cancer drug as maintenance therapy [https://seekingalpha.com/news/4503836-pfizer-posts-late-stage-trial-win-cancer-drug]